| Background: | Fas ligand (FasL/CD178/CD95L) is a type II-membrane protein, belonging the tumor necrosis factor (TNF)/nerve growth factor (NGF) family. It is known that engagement of Fas (receptor of FasL) by FasL causes apoptotic cell death. FasL is predominantly expressed in activated T lymphocytes and Natural Killer (NK) cells and expressed in the tissues of the immune-privilege sites such as the testis and eye. On the other hand, Fas is expressed in various tissues with abundant expression in the thymus, liver, heart, and kidney. Furthermore, a variety of cancers such as melanomas were found to express FasL in addition to Fas. It is said that the Fas/FasL system is involved in the deletion of dangerous activated or autoreactive T and B cells, and in turn plays a role in human diseases such as fulminant hepatitis, AIDS, cancers and other diseases involving CTL-induced tissue destruction. Furthermore, FasL can be used as an immune-suppressive agent. Rejection of transplants is mediated by activated T cells that may express functional Fas. If a transplanted tissue is engineered to express FasL or is co-transplanted with FasL-expressing cells, the transplant may be tolerated. |
| Clonality: | Monoclonal |
| Clone Number: | 4H9 |
| Formulation: | 1.0 mg/mL in PBS/50% glycerol, pH 7.2 |
| Gene ID Human: | 355 |
| Gene ID Mouse: | 14102 |
| Host Species: | Hamster |
| Immunogen: | Recombinant Human Fas ligand |
| Regulatory Statement: | For Research Use Only. Not for use in diagnostic procedures. |
| Isotype: | IgG |
| Product Type: | Primary Antibody |
| Shipping: | 4 |
| Size: | 100 μg |
| Species Reactivities: | Human |
| Status: | RUO |
| Storage: | -20℃ |
| Target: | Fas |
Applications: ELISA, FCM, NT
| ELISA: | Optimal Dilution to be determined by end user. |
| FCM: | 10 ug/mL (final concentration) |
| NT: | Optimal Dilution to be determined by end user. |
There are no references for Anti-Fas Ligand (CD178) (Human) mAb at this time.
